| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910705864103321 |
|
|
Titolo |
The decline of economic opportunity in the United States : causes and consequences : hearing before the Joint Economic Committee, Congress of the United States, One Hundred Fifteenth Congress, first session, April 5, 2017 |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Washington : , : U.S. Government Publishing Office, , 2017 |
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (iii, 99 pages) : illustrations |
|
|
|
|
|
|
Collana |
|
|
|
|
|
|
Soggetti |
|
Economic development - United States |
Recessions - United States |
Unemployment - United States |
Social mobility - United States |
American Dream |
Legislative hearings. |
United States Economic conditions 2009- |
United States Economic policy 2009- |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Paper version available for sale by the Superintendent of Documents, United States Government Publishing Office. |
|
|
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910557615103321 |
|
|
Autore |
Ruvo Menotti |
|
|
Titolo |
Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy 2.0 |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (112 p.) |
|
|
|
|
|
|
Soggetti |
|
Biology, life sciences |
Research & information: general |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Sommario/riassunto |
|
Monoclonal antibodies (mAbs) are among the most specialised molecules for the recognition and capture of specific analytes. Hundreds of thousands of mAbs have been generated for a large number of different antigens with increasing affinity and specificity and are available for the most diverse purposes. Many of them have been validated as irreplaceable agents for diagnosis and therapy or as unique reagents for research. Others have been developed using emerging technologies that avoid the need for animal immunisation. This short book strives to gather the perspective view of the various contributing authors and to survey the new strategic assets adopted to generate novel monoclonal antibodies or surrogates, such as Fab, Fab2, ScFv and nanobodies, which have an increasing impact in biomedicine as therapeutic or diagnostic assets in various diseases. |
|
|
|
|
|
|
|
| |